Wie behandelt man die Colitis ulcerosa? – Lokalisation und Schweregrad sind entscheidend

Die Colitis ulcerosa ist neben dem Morbus Crohn die wichtigste chronisch entzündliche Darmerkrankung. Im vorliegenden Artikel werden die Therapieprinzipien in Form eines Algorithmus entsprechend der Deutschen Leitlinie der DGVS und der neuen Europäischen Leitlinie zur Behandlung der Colitis ulcerosa dargestellt. Die Basis der Therapie beruht auf einer Suppression der inflammatorischen Reaktion. Diese kann im Falle der Aminosalicylate je nach Befallsmuster topisch oder systemisch erfolgen. Bei schwerem Befall kommen Steroide zum Einsatz, häufig sind Immunsuppressiva wie Azathioprin, bei refraktären Verläufen auch von Reservemedikamenten wie Cyclosporin, Tacrolimus oder Infliximab indiziert.

Ulcerative colitis represents one of the main chronic inflammatory bowel diseases. This review highlights therapeutic principles according to the National (DGVS) and European (ECCO) guidelines. In general to date therapy relies on the suppression of the inflammatory mucosal process. 5-Aminosalicylates may be given topically and/or systemically according to the localisation and extend of disease. In severe ulcerative colitis systemic steroids represent the mainstay of therapy whereas in refractory disease rescue medication like cyclosporine, tacrolimus or infliximab are indicated.

Ulcerative colitis - 5-ASA - cylosporine - tacrolimus - azathioprine - infliximab

Literatur

• 1 Ho GT, Chiam P, Drummond H et al.. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort.  Aliment Pharmacol Ther. 2006;  24 319-330
• 2 Faubion WA, Loftus EV, Harmsen WS et al.. The natural history of corticosteroid therapy for inflammatory bowel disease: a population based study.  Gastroenterology. 2001;  121 250-260
• 3 Hoffmann JC, Zeitz M, Bischoff SC et al.. Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease.  Z Gastroenterol. 2004;  42 979-983
• 4 Travis SPL, Stange EF, Léman M et al.. European-evidence-based consensus on the management of ulcerative colitis: Current management.  J Crohns Colitis. 2008;  2 24-62
• 5 Marshall JK, Irvine EJ.. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis.  Aliment Pharm Ther. 1995;  9 293-300
• 6 Sutherland L, Roth D, Beck P et al.. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.. Cochrane Database Syst Rev CD 000543 2006
• 7 Kruis W, Kiudelis G, Rácz I et al.. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.  Gut. 2009;  58 233-240
• 8 Marteau P, Probert CS, Lindgren S et al.. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.  Gut. 2005;  54 960-965
• 9 Ogata H, Matsui T, Nakamura M et al.. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.  Gut. 2006;  55 1255-1262
• 10 Rutgeerts P, Sandborn WJ, Feagan BG et al.. Infliximab for induction and maintenance therapy for ulcerative colitis.  N Engl J Med. 2005;  353 2462-2476
• 11 Sutherland L, Roth D, Beck P et al.. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.. Cochrane Database Syst Rev CD 000544 2002
• 12 Stremmel W, Merle U, Zahn A et al.. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis.  Gut. 2005;  54 966-971

Korrespondenz